ReviewGastro hep advances2026
Food Insecurity and Chronic Liver and Gastrointestinal Conditions: A Systematic Review of Prevalence and Clinical Outcomes.
Review in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Food insecurity (FI), limited or uncertain access to enough food, has been linked to poor clinical outcomes. Given that dietary management is central to many gastrointestinal (GI) and hepatologic diseases, these populations may be uniquely vulnerable to the effects of FI. Our primary aim was to determine the prevalence rates of FI among patients with chronic GI and liver conditions within the United States and evaluate reported associations with clinical outcomes. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic search of PubMed, Web of Science, and Embase from inception to July 17, 2025. Eligible studies reported FI prevalence and were conducted in the United States. Clinical and nutritional outcomes were collected as well as risk of bias assessment for each study. Results: Of the 1279 references identified, 25 studies (54,034 participants) meet inclusion criteria. FI prevalence varied widely (5%-45.5%) across disease types, including liver disease (n = 12), inflammatory bowel disease (n = 5), cystic fibrosis (n = 5), and celiac disease (n = 3). Eight studies utilized the gold standard, 18-item US Household Food Security Survey. Of the 17 studies reporting clinical outcomes, 13 found possible associations with FI. Seventeen out of 25 studies met ≥80% of quality criteria. The most commonly unmet criteria across studies related to insufficient control of confounding variables. Conclusion: FI is prevalent and clinically significant across a range of chronic GI and hepatologic conditions. Though prevalence estimates vary substantially by disease type and measurement approach, FI may be associated with worse clinical outcomes, dietary nonadherence, and social disadvantage. Routine screening and intervention strategies to address FI may be a critical component to comprehensive GI care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.